Literature DB >> 9603341

Overexpression, purification and helix-destabilizing properties of Epstein-Barr virus ssDNA-binding protein.

T Tsurumi1, J Kishore, N Yokoyama, M Fujita, T Daikoku, H Yamada, Y Yamashita, Y Nishiyama.   

Abstract

The Epstein-Barr virus (EBV) ssDNA-binding protein (SSB) encoded by the BALF2 gene is one of the essential replication proteins in the lytic phase of EBV DNA replication. In order to obtain the amount of EBV SSB required for characterization, a recombinant baculovirus containing the complete sequence of the BALF2 open reading frame under the control of the baculovirus polyhedrin promoter was constructed. Insect cells infected with the recombinant virus produced a protein of 130 kDa, recognized by anti-BALF2 protein-specific polyclonal antibody. The overexpressed EBV SSB was purified homogeneously from the cytosolic fraction of the recombinant virus-infected cells. The purified protein displaced short DNA strands from their complementary sequences in the single-stranded form of M13. The helix-destabilizing activity was neutralized by the anti-BALF2 protein-specific antibody. Maximum unwinding occurred at EBV SSB concentrations exceeding saturation level of the DNA substrate. The DNA unwinding reaction mediated by the EBV SSB was highly cooperative and extremely rapid. The reaction displayed no directionality and required neither ATP nor MgCl2, two essential cofactors for DNA helicase activity. The helix-destabilizing property of the EBV SSB may function to melt out secondary structures on the ssDNA template, thereby facilitating the movement of the EBV DNA polymerase.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9603341     DOI: 10.1099/0022-1317-79-5-1257

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  8 in total

1.  The Epstein-Barr virus pol catalytic subunit physically interacts with the BBLF4-BSLF1-BBLF2/3 complex.

Authors:  K Fujii; N Yokoyama; T Kiyono; K Kuzushima; M Homma; Y Nishiyama; M Fujita; T Tsurumi
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

2.  Identification and characterization of the helix-destabilizing activity of rotavirus nonstructural protein NSP2.

Authors:  Z F Taraporewala; J T Patton
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

3.  Inhibition of S-phase cyclin-dependent kinase activity blocks expression of Epstein-Barr virus immediate-early and early genes, preventing viral lytic replication.

Authors:  Ayumi Kudoh; Tohru Daikoku; Yutaka Sugaya; Hiroki Isomura; Masatoshi Fujita; Tohru Kiyono; Yukihiro Nishiyama; Tatsuya Tsurumi
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

4.  Initiation of Epstein-Barr virus lytic replication requires transcription and the formation of a stable RNA-DNA hybrid molecule at OriLyt.

Authors:  Andrew J Rennekamp; Paul M Lieberman
Journal:  J Virol       Date:  2010-12-29       Impact factor: 5.103

5.  Spatiotemporally different DNA repair systems participate in Epstein-Barr virus genome maturation.

Authors:  Atsuko Sugimoto; Teru Kanda; Yoriko Yamashita; Takayuki Murata; Shinichi Saito; Daisuke Kawashima; Hiroki Isomura; Yukihiro Nishiyama; Tatsuya Tsurumi
Journal:  J Virol       Date:  2011-04-13       Impact factor: 5.103

6.  Initiation of lytic DNA replication in Epstein-Barr virus: search for a common family mechanism.

Authors:  Andrew J Rennekamp; Paul M Lieberman
Journal:  Future Virol       Date:  2010-01       Impact factor: 1.831

7.  Reovirus protein sigmaNS binds in multiple copies to single-stranded RNA and shares properties with single-stranded DNA binding proteins.

Authors:  A L Gillian; S C Schmechel; J Livny; L A Schiff; M L Nibert
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

8.  Nuclear transport of Epstein-Barr virus DNA polymerase is dependent on the BMRF1 polymerase processivity factor and molecular chaperone Hsp90.

Authors:  Daisuke Kawashima; Teru Kanda; Takayuki Murata; Shinichi Saito; Atsuko Sugimoto; Yohei Narita; Tatsuya Tsurumi
Journal:  J Virol       Date:  2013-04-03       Impact factor: 5.103

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.